Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis Talbot

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Cancer Immunology Research|January 30, 2024
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple MyelomaNathalie Roders, Cecilia Nakid-Cordero, Fabio Raineri, et al.
British Journal of Haematology|April 8, 2022
Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patientsDikelele Elessa, Pierre-Edouard Debureaux, Camille Villesuzanne, et al.
Hemasphere|June 19, 2026
CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myelomaBenoît Ferment, Amani Ouedrani, Alexis Talbot, et al.
Frontiers in Immunology|December 26, 2022
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life studyPierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, et al.
Ejhaem|September 2, 2022
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatmentAudrey Abecassis, Nathalie Roders, Maxime Fayon, et al.
Transplantation|September 25, 2012
Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantationAnna D Petropoulou, Raphael Porcher, Regis Peffault de Latour, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 25, 2024
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter studyMartin Nicol, Cassiel Kitzinger, Mathilde Baudet, et al.
JMIR Formative Research|February 25, 2026
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)Alexis Talbot, Bernard Delcour, Laurent Gillot, et al.
Hemasphere|July 31, 2024
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life studyAxel André, Lydia Montes, Damien Roos-Weil, et al.
Cell|January 13, 2023
An evolved AAV variant enables efficient genetic engineering of murine T cellsWilliam A Nyberg, Jonathan Ark, Angela To, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Cancer Immunology Research|January 30, 2024
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple MyelomaNathalie Roders, Cecilia Nakid-Cordero, Fabio Raineri, et al.
British Journal of Haematology|April 8, 2022
Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patientsDikelele Elessa, Pierre-Edouard Debureaux, Camille Villesuzanne, et al.
Hemasphere|June 19, 2026
CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myelomaBenoît Ferment, Amani Ouedrani, Alexis Talbot, et al.
Frontiers in Immunology|December 26, 2022
Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life studyPierre-Edouard Debureaux, Stéphanie Harel, Nathalie Parquet, et al.
Ejhaem|September 2, 2022
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatmentAudrey Abecassis, Nathalie Roders, Maxime Fayon, et al.
Transplantation|September 25, 2012
Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantationAnna D Petropoulou, Raphael Porcher, Regis Peffault de Latour, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 25, 2024
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter studyMartin Nicol, Cassiel Kitzinger, Mathilde Baudet, et al.
JMIR Formative Research|February 25, 2026
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)Alexis Talbot, Bernard Delcour, Laurent Gillot, et al.
Hemasphere|July 31, 2024
Impact of second autologous stem-cell transplantation at relapsed multiple myeloma: A French multicentric real-life studyAxel André, Lydia Montes, Damien Roos-Weil, et al.
Cell|January 13, 2023
An evolved AAV variant enables efficient genetic engineering of murine T cellsWilliam A Nyberg, Jonathan Ark, Angela To, et al.
Pageof 7